The ROE as of November 2024 (TTM) for Nuvectis Pharma, Inc. (NVCT) is -155.80%

According to Nuvectis Pharma, Inc.’s latest financial reports and current stock price. The company's current ROE is -155.80%. This represents a change of 296.55% compared to the average of -39.29% of the last 4 quarters.

Nuvectis Pharma, Inc. (NVCT) Historical ROE (quarterly & annually)

How has NVCT ROE performed in the past?

The mean historical ROE of Nuvectis Pharma, Inc. over the last ten years is -24.38%. The current -155.80% ROE has changed 539.10% with respect to the historical average. Over the past ten years (40 quarters), NVCT's ROE was at its highest in in the June 2021 quarter at 134.95%. The ROE was at its lowest in in the December 2023 quarter at -54.27%.

Nuvectis Pharma, Inc. (NVCT) ROE by Quarter and Year

Discovering the peaks and valleys of Nuvectis Pharma, Inc. ROE, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.

Nuvectis Pharma, Inc. (NVCT) Average ROE

How has NVCT ROE performed in the past?

The current ROE of Nuvectis Pharma, Inc. (NVCT) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages

Nuvectis Pharma, Inc. (NVCT) ROE vs. Peers

How is NVCT’s ROE compared to its peers?

Nuvectis Pharma, Inc.’s ROE is greater than Replimune Group, Inc. (-53.12%), greater than Lyra Therapeutics, Inc. (-178.68%), greater than Kronos Bio, Inc. (-64.55%), greater than Gossamer Bio, Inc. (-127.28%), greater than Olema Pharmaceuticals, Inc. (-53.55%), greater than Larimar Therapeutics, Inc. (-35.87%), greater than Centessa Pharmaceuticals plc (-52.22%), greater than Orchestra BioMed Holdings, Inc. (-107.04%), greater than Monte Rosa Therapeutics, Inc. (-62.68%), greater than NewAmsterdam Pharma Company N.V. (-53.79%), less than Inventiva S.A. (524.89%), greater than Cullinan Oncology, Inc. (-26.54%), greater than Compass Therapeutics, Inc. (-28.67%), greater than Ikena Oncology, Inc. (-39.59%), greater than Aerovate Therapeutics, Inc. (-90.19%), greater than Eliem Therapeutics, Inc. (-47.03%), greater than Decibel Therapeutics, Inc. (-56.38%), greater than Anebulo Pharmaceuticals, Inc. (-184.40%), greater than Werewolf Therapeutics, Inc. (-58.83%), greater than Edgewise Therapeutics, Inc. (-26.83%), greater than Celcuity Inc. (-62.66%), greater than C4 Therapeutics, Inc. (-42.45%),

Build a custom stock screener for Nuvectis Pharma, Inc. (NVCT) and other stocks

One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Nuvectis Pharma, Inc. using the financials and key metrics that matter to you in a single view.

The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:

Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.

Get your free trial here.

Nuvectis Pharma, Inc. (NVCT) and other stocks custom spreadsheet templates

The easiest way to analyze a company like Nuvectis Pharma, Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.

Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.

Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.